Search - tctmd.com

Displaying 141 - 160 of 326

Sort: Relevancy | Date

News Daily News

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

Todd Neale

October 29, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News TCT 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

Todd Neale

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

News Conference News CRT 2019

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Yael L. Maxwell

March 07, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

Todd Neale

January 16, 2019

Advertisement

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

Recurrent Events Common Among Young Patients With CAD

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content